公开(公告)号：US20120108452A1

公开(公告)日：2012-05-03

申请号：US13044496

申请日：2011-03-09

申请人： David Neujahr ,  Aminu Mohammed ,  Jeffrey Rossio

发明人： David Neujahr ,  Aminu Mohammed ,  Jeffrey Rossio

IPC分类号： C40B30/04 ,  G01N33/566

CPC分类号： G01N33/6893 ,  G01N33/6884 ,  G01N2333/521 ,  G01N2333/54 ,  G01N2333/5437 ,  G01N2800/12 ,  G01N2800/245

摘要： Described and disclosed are methods for determining, predicting, diagnosing, treating, and monitoring lung diseases, including bronchiolitis obliterans syndrome and acute cellular rejection in a lung transplant recipient by measuring chemokine levels in bronchoalveolar lavage (BAL) samples. The chemokine CXCL10 is measured in combination with at least one analyte selected from the group consisting of IL1RA, CXCL11, MCP-1, CXCL9, RANTES, IL-13, IL-17, IL-22, fractalkine, and eotaxin; and/or biomarkers. The present teachings also relate to methods, treatment decisions and kits for detecting and monitoring onset of lung transplant rejection in advance of clinically recognized symptoms.

摘要翻译： 描述和公开了通过测量支气管肺泡灌洗（BAL）样品中的趋化因子水平来确定，预测，诊断，治疗和监测肺部疾病的方法，包括闭塞性细支气管炎综合征和肺移植受体中的急性细胞排斥反应。 与至少一种选自IL1RA，CXCL11，MCP-1，CXCL9，RANTES，IL-13，IL-17，IL-22，fractalkine和嗜酸细胞活化趋化因子的分析物组合测量趋化因子CXCL10; 和/或生物标志物。 本教导还涉及在临床认可的症状之前检测和监测肺移植排斥发作的方法，治疗决定和试剂盒。